Growth Forecast for Typhoid Vaccines Market Through 2035

Market Overview

The global Typhoid Fever Vaccines Market was valued at approximately USD 0.51 billion in 2025, with projections suggesting it could grow to USD 1.25 billion by 2035. This growth, estimated at a compound annual growth rate (CAGR) of 9.36% from 2026 to 2035, reflects increasing initiatives to prevent typhoid fever worldwide.

This market growth can be largely attributed to several key factors, including the rollout of typhoid conjugate vaccines (TCVs) supported by the World Health Organization (WHO) and Gavi. Additionally, the emergence of antimicrobial-resistant strains of Salmonella Typhi and large-scale vaccination campaigns in regions like South Asia and Africa are contributing to the uptick in vaccine use.

Conjugate vaccines are particularly beneficial as they offer effective protection for children starting at six months of age with just a single dose. WHO’s prequalification of multiple TCV suppliers has increased availability and reduced costs, with public tender prices now below USD 2 per dose. Also noteworthy is the resurgence of international travel, which has elevated demand among travelers heading to areas where typhoid is common.

Current Trends in Vaccination

A significant example of proactive vaccination strategies occurred in October 2025, when a campaign rolled out TCVs across 33 Rohingya camps in Cox’s Bazar, Bangladesh. Targeted at children aged nine months to 15 years, this initiative underscores the utility of TCVs in emergency situations that are often marked by overcrowding and inadequate sanitation, both of which heighten the risk of typhoid outbreaks.

• Increased integration of Gavi-supported TCVs into routine immunization schedules for infants.
• Heightened use of mass vaccination campaigns in response to drug-resistant typhoid strains.
• Growing number of suppliers gaining WHO prequalification, leading to decreased prices.
• Expansion of local vaccine production capacity in areas like South Asia and Africa.
• Advancements in developing combined vaccines, including those targeting both typhoid and paratyphoid fever.

Outlook for the U.S. Market

The U.S. segment of the Typhoid Fever Vaccines Market was valued at USD 56.24 million in 2025, with expectations to reach USD 104.83 million by 2035, growing at a CAGR of 6.42%.

A steady demand from international travelers, military personnel, and laboratory workers has proved pivotal to this market's expansion. Most cases of typhoid fever in the U.S. are linked to travel to endemic regions, which has led the CDC to recommend vaccinations for those planning to visit these areas. The two vaccines available in the U.S. are the injectable Vi polysaccharide vaccine (Typhim Vi) and the oral live attenuated vaccine (Vivotif). Travel clinics, pharmacies, and hospital services primarily administer these vaccines.

In a notable update, Bavarian Nordic completed its acquisition of Emergent BioSolutions’ travel health division in 2023, a move that included the oral typhoid vaccine, Vivotif, enhancing the company's offerings in the travel vaccine market.

Segment Analysis

By vaccine type, the Vi polysaccharide (Vi-PS) vaccine led the market in 2025, holding a share of approximately 41.86%. Meanwhile, the conjugate vaccine (TCV) is noted as the fastest-growing segment, with a CAGR of about 13.14%, reflecting the shift towards more effective and longer-lasting immunization strategies.

Injection administration dominated the market with a 64.18% share, though oral vaccines exhibit the fastest growth rate at around 10.62%. In terms of age groups, the segment for children aged 6 to 15 held a significant market share and is expected to continue expanding, especially as new countries implement catch-up vaccination initiatives.

Public health programs accounted for over half of the market's share, while vaccination services in travel clinics and pharmacies are rapidly growing, spurred on by ongoing recovery in global travel. The increasing awareness of drug-resistant typhoid among travelers further propels this demand.

Regional Insights

In 2025, North America made up about 12.84% of the Typhoid Fever Vaccines Market, with the U.S. leading in sales. The CDC promotes vaccination for travelers to endemic regions, significantly impacting demand for Typhim Vi and Vivotif.

Europe, especially the UK, Germany, and France, has notable contributions to this market. The rise in reported cases of drug-resistant typhoid has prompted health authorities to recommend vaccinations before travel to endemic areas.